NCT04185246View on ClinicalTrials.gov

A Dose Ascending Study to Evaluate the Safety of NH002 as a Contrast Agent in Cardiac Echocardiography

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 4, 2019

Primary Completion Date

July 1, 2020

Study Completion Date

July 1, 2020

Conditions
Cardiac Disease
Interventions
DRUG

NH002 (Perflutren Lipid Microspheres) Injectable Suspension

NH002 is formulated as a microbubble injectable suspension for intravenous administration. NH002 requires an activation process prior to use.

DIAGNOSTIC_TEST

Echocardiogram

Each patient will undergo an unenhanced ultrasound examination and a NH002 contrast-enhanced examination on the same day.

Trial Locations (2)

10449

Taipei Mackay Memorial Hospital, Taipei

11217

Taipei Veterans General Hospital, Taipei

All Listed Sponsors
collaborator

StatPlus,Inc.

UNKNOWN

lead

Trust Bio-sonics, Inc.

INDUSTRY

NCT04185246 - A Dose Ascending Study to Evaluate the Safety of NH002 as a Contrast Agent in Cardiac Echocardiography | Biotech Hunter | Biotech Hunter